Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Usmani SZ, et al. Among authors: vorobyev v. Haematologica. 2022 Oct 1;107(10):2408-2417. doi: 10.3324/haematol.2021.279459. Haematologica. 2022. PMID: 35354247 Free PMC article. Clinical Trial.
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Mateos MV, et al. Among authors: vorobyev v. Lancet Haematol. 2020 May;7(5):e370-e380. doi: 10.1016/S2352-3026(20)30070-3. Epub 2020 Mar 23. Lancet Haematol. 2020. PMID: 32213342 Clinical Trial.
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
Dimopoulos M, Bringhen S, Anttila P, Capra M, Cavo M, Cole C, Gasparetto C, Hungria V, Jenner M, Vorobyev V, Ruiz EY, Yin JY, Saleem R, Hellet M, Macé S, Paiva B, Vij R. Dimopoulos M, et al. Among authors: vorobyev v. Blood. 2021 Mar 4;137(9):1154-1165. doi: 10.1182/blood.2020008209. Blood. 2021. PMID: 33080623 Free PMC article. Clinical Trial.
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Bringhen S, Pour L, Vorobyev V, Vural F, Warzocha K, Benboubker L, Koh Y, Maisnar V, Karlin L, Pavic M, Campana F, Le Guennec S, Menas F, van de Velde H, Richardson PG. Bringhen S, et al. Among authors: vorobyev v. Leuk Res. 2021 May;104:106576. doi: 10.1016/j.leukres.2021.106576. Epub 2021 Mar 29. Leuk Res. 2021. PMID: 33839618 Free article. Clinical Trial.
[Follicular lymphoma. High-dose immunochemotherapy with autologous blood stem cell transplantation: Results of the first prospective study in Russia].
Nesterova ES, Kravchenko SK, Mangasarova YK, Baryakh EA, Misyurina AE, Vorobyev VI, Plastinina LV, Chernova NG, Kovrigina AM, Obukhova TN, Klyasova GA, Shevelev AA, Kostina IE, Gemdzhian EG, Gaponova TV, Vorobyev AI. Nesterova ES, et al. Among authors: vorobyev vi, vorobyev ai. Ter Arkh. 2016;88(7):62-71. doi: 10.17116/terarkh201688762-71. Ter Arkh. 2016. PMID: 27459617 Clinical Trial. Russian.
[Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
Vorobyev VI, Gemdzhian EG, Fedorova LV, Mikhailova NB, Ilyasov RK, Kaleikina LP, Trubyakova OS, Kaplanov KD, Melnichenko EV, Martynova EV, Yakovleva EP, Li OY, Tarasenko EV, Chumakova EP, Bulieva NB, Nesterova ES, Margolin OV, Zherebtsova VA, Butaev LS, Ptushkin VV. Vorobyev VI, et al. Ter Arkh. 2021 Jul 23;93(7):770-777. doi: 10.26442/00403660.2021.07.200930. Ter Arkh. 2021. PMID: 36286727 Russian.
[Therapy for Burkitt's lymphoma according to the BL-M-04 protocol: 12-year experience].
Baryakh EA, Tyurina NG, Vorobyev VI, Gemdzhyan EG, Mangasarova YK, Klyasova GA, Kovrigina AM, Obukhova TN, Zvonkov EE, Vernyuk MA, Chervontseva AM, Polyakov YY, Misyurina АЕ, Valiev TT, Zherebtsova VA, Magomedova AU, Galstyan GM, Yatskov KV, Nesterova ES, Vorobyev AI, Kravchenko SK. Baryakh EA, et al. Among authors: vorobyev vi, vorobyev ai. Ter Arkh. 2015;87(7):4-14. doi: 10.17116/terarkh20158774-14. Ter Arkh. 2015. PMID: 26390720 Russian.
287 results